This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To investigate striatal adenosine A2A receptor availability in patients with Parkinson disease (PD) with and without levodopa-induced dyskinesias (LIDs). While providing effective relief from the motor symptoms of PD, chronic levodopa use is associated with development of LIDs. A2A receptors are expressed on the bodies of indirect pathway medium spiny striatal neurons and on dopamine terminals and play a role in modulating dopamine transmission. A2A antagonists have antiparkinsonian activity by boosting levodopa efficacy. We aimed to study A2A receptor availability in patients with PD with and without LIDs using PET and [11C]SCH442416, an A2A antagonist.
Methods: Six patients with PD with and 6 without LIDs were studied withdrawn 12 hours from medication. Their PET findings were compared with 6 age-matched healthy controls. Using spectral analysis, [11C]SCH442416 regional volumes of distribution (VT) were computed for the caudate, putamen, and thalamus and binding potentials (BPND) reflecting the ratio of specific:nonspecific uptake were compared between groups.
Results: A2A binding in the caudate and putamen of subjects with PD with LIDs was far higher (p = 0.026 and p = 0.036, respectively) than that of subjects with PD without LIDs, which lay within the control range. Thalamic A2A availability was similar for all 3 groups.
Conclusion: Patients with PD with LIDs show increased A2A receptor availability in the striatum. This finding is compatible with altered adenosine transmission playing a role in LIDs and provides a rationale for a trial of A2A receptor agents in the treatment of these motor complications.
Footnotes
Study funding: Supported by the Parkinsons Disease Society UK.
-
- ANCOVA
- analysis of covariance
- GPe
- external pallidum
- GPi
- globus pallidus interna
- H&Y
- Hoehn &Yahr
- LED
- levodopa effective dose
- LEU
- levodopa equivalent unit
- LID
- levodopa-induced dyskinesia
- MPTP
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
- PD
- Parkinson disease
- PPE
- preproenkephalin
- ROI
- region of interest
- SNpr
- substantia nigra pars reticulata
- UPDRS
- Unified Parkinson's Disease Rating Scale.
- Received September 23, 2010.
- Accepted February 10, 2011.
- Copyright © 2011 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Topics Discussed
Alert Me
Recommended articles
Putaminal serotonergic innervation
Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores
Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD
A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease